Piroth Lionel, Pechinot André, Di Martino Vincent, Hansmann Yves, Putot Alain, Patry Isabelle, Hadou Tahar, Jaulhac Benoit, Chirouze Catherine, Rabaud Christian, Lozniewski Alain, Neuwirth Catherine, Chavanet Pascal, Minello Anne
Département d'Infectiologie, CHU Dijon, Dijon, France.
BMC Infect Dis. 2014 May 23;14:287. doi: 10.1186/1471-2334-14-287.
Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed.
An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010-2011.
Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 as confirmed bacterascites. The predominant flora was Gram-positive cocci, whatever the situation (SBP, bacterascites, nosocomial/health-care related or not). Enteroccocci (27.7% E. faecium) were isolated in 24% of the episodes, and in 48% from patients receiving quinolone prophylaxis. E. coli were susceptible to amoxicillin-clavulanate and to third-generation cephalosporins in 62.5% and 89.5% of cases, respectively. No single antibiotic allowed antimicrobial coverage of more than 60%. Only combinations such as amoxicillin + third-generation cephalosporin or cotrimoxazole allowed coverage close to 75-80% in non-nosocomial episodes. Combinations based on broader spectrum antibiotics should be considered for empirical therapy of nosocomial infections.
Our study confirmed the changing spectrum of pathogens in SBP and bacterascites, and the need for more complex antibiotic strategies than those previously recommended. Our findings also underline the need for new clinical trials conducted in the current epidemiological context.
目前关于自发性细菌性腹膜炎(SBP)经验性抗菌治疗的建议是基于相当陈旧的试验。由于微生物流行病学和患者管理已经发生变化,这些建议是否仍然合适必须得到证实。
2010年至2011年在法国四家大学医院进行了一项观察性研究,详尽收集了与腹水培养阳性相关的临床和生物学数据。
在190例肝硬化患者(中位年龄61.5岁,58.5%为Child C级)中观察到268份有记录的阳性培养结果。其中,57例被分类为确诊的SBP,140例为确诊的菌腹水。无论何种情况(SBP、菌腹水、与医院/医疗保健相关或无关),主要菌群都是革兰氏阳性球菌。在24%的病例中分离出肠球菌(27.7%为粪肠球菌),在接受喹诺酮预防的患者中这一比例为48%。大肠杆菌分别对阿莫西林-克拉维酸和第三代头孢菌素的敏感率为62.5%和89.5%。没有一种单一抗生素的抗菌覆盖率超过60%。只有阿莫西林+第三代头孢菌素或复方新诺明等联合用药在非医院感染病例中的覆盖率接近75%-80%。对于医院感染的经验性治疗,应考虑基于更广谱抗生素的联合用药。
我们的研究证实了SBP和菌腹水中病原体谱的变化,以及需要比先前建议的更复杂的抗生素策略。我们的研究结果还强调了在当前流行病学背景下进行新的临床试验的必要性。